Screener / SEC EDGAR /CIK 0001604821 /10-K filed Feb 27, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Labs

Natera, Inc. NTRA

Compare with peers Embed
The 10-K against last year's

83 changes: 11 added, 12 removed, 58 reworded, 2 quiet changes

10-K Feb 27, 2026 vs Feb 28, 2025

10-K 0001104659-26-020881 (Feb 27, 2026) vs 10-K 0001558370-25-001869 (Feb 28, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

242 paragraphs · 8 new · 48 reworded · 7 gone · 10-K Feb 27, 2026 against Feb 28, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 137 · 44% changed Every version of it
The FDA has granted us Breakthrough Device designations indication for our Signatera test covering its use in various applications. While receiving such designations enables us to have increased interactions with FDA, which we seek approval, and we cannot assure you that these designations will lead to approval, or accelerated review or approval approval, of our regulatory submissions for Signatera.
Paragraph 130 · 41% changed Every version of it
We currently offer a number of genetic tests, and each of those tests is an LDT. The FDA considers an LDT to be a test that is designed, developed, validated and used within a single laboratory. Our laboratories are currently regulated under CLIA and must comply with CAP requirements, and we are subject to extensive federal and state laws and regulations. The FDA has historically taken the position that it has the authority to regulate LDTs as medical devices under the FDC Act, but it had generally exercised enforcement discretion with regard to such tests. The issued a final rule issued by FDA in May 2024, discussed 2024 that would have subjected many LDTs to regulatory requirements including, in some cases, premarket authorization. A federal district court vacated the section of this Annual Report on Form 10-K entitled “Business—Government Regulations—FDA”, could have FDA final rule in May 2025, holding that LDTs are not subject to FDA regulation. FDA rescinded the final rule in September 2025. FDA has not indicated how it will interpret the court ruling or whether it will seek a significant impact on our ability to market current LDTs and to develop new ones in the future. Although our LDTs marketed prior to May 6, 2024 may be eligible for enforcement discretion different regulatory approach with respect to premarket review requirements, changes we make LDTs or components thereof. In June 2025 Congress re-introduced the Verifying Accurate, Leading-edge IVCT Development Act, or VALID Act, to establish a new risk-based regulatory framework for in vitro clinical tests, or IVCTs, including IVDs, LDTs, collection devices and instruments used with such LDTs, as well as new LDTs we develop after that date, will be subject to various regulatory requirements such as those described tests. This legislation was previously introduced in this risk factor. 2021 and 2023.
Paragraph 145 · 33% changed Every version of it
The clinical laboratory testing industry is highly regulated, and failure to comply with applicable regulatory, supervisory, accreditation, registration or licensing requirements may adversely affect our business, financial condition and results of operations. In particular, the laws and regulations governing the marketing and research of clinical diagnostic testing are extremely complex and in many instances there are no clear regulatory or judicial interpretations of these laws and regulations, increasing the risk that we may be found to be in violation of these laws.
Paragraph 86 · 30% changed Every version of it
We are involved in legal matters, including investigations, subpoenas, demands, disputes, litigation, requests for information, and other regulatory or administrative actions or proceedings, including those with respect to intellectual property, testing and test performance, billing, reimbursement, marketing, short seller and media allegations, employment, and other matters. See Note 8—Commitments 10—Commitments and Contingencies—Legal Proceedings for a description of our legal matters. An independent committee of our board of directors initiated and completed an internal investigation into the allegations made in a March 2022 short seller report, with the assistance of the law firm of WilmerHale LLP, or WilmerHale. WilmerHale had access to company executives, personnel, records, communications, and documents. Based on the investigation, the independent committee, on behalf of the board, concluded that the allegations of wrongdoing against the Company in the report were unfounded.
Paragraph 136 · 30% changed Every version of it
In addition, The FDA has granted us Breakthrough Device designations for our Signatera test covering its use in various applications. While receiving such designations enables us to have increased interactions with FDA, this designation does not change the requirement that we cannot assure you that these designations will lead to accelerated review or approval demonstrate the safety and effectiveness of our regulatory submissions tests for Signatera. each
Paragraph 65 · 25% changed Every version of it
The marketing, sale and use of our tests could lead to product liability claims against us if someone were to allege that our test failed to perform as it was designed or as claimed in our promotional materials, was performed pursuant to incorrect or inadequate laboratory procedures, if we delivered incorrect or incomplete test results or our test failed to produce a result, or if someone were to misinterpret test results. In addition, we may be subject to liability for errors in, a misunderstanding of, or inappropriate reliance upon, the information we provide, or for failure to provide such information, in connection with our marketing and promotional activities or as part of the results generated by our tests. For example, Panorama could provide a low-risk result which a patient or physician may rely upon to make a conclusion about the health of the fetus, which may, in fact, have the condition for which we delivered a low-risk result because the Panorama result was a so-called false negative. Similarly, Panorama could provide a so-called false positive, which is a high-risk result for a fetus that may not, in fact, have the relevant condition. Even though Panorama and our other tests are highly accurate, they are not 100% accurate and we may report false negative or false positive results, which may subject us to lawsuits claiming product or professional liability or other claims, as has happened in the past and may happen in the future. A product liability or professional liability claim could result in substantial damages and be costly and time-consuming for us to defend. Although we maintain product and professional liability insurance, our insurance may not fully protect us from the financial impact of defending against product liability or professional liability claims or any judgments, fines or settlement costs arising out of any such claims. Any product liability or professional liability claim brought against us, with or without merit, could increase our insurance rates, cause our insurance coverage to be terminated, or prevent us from securing insurance coverage in the future. Additionally, any product liability or professional liability lawsuit could harm our reputation, result in a cessation of our services, or cause our partners to terminate our agreements with them, any of which could adversely impact our results of operations.
Paragraph 139 · 24% changed Every version of it
Failure to obtain necessary regulatory approvals may adversely affect our ability to expand our operations internationally, including our ability to continue commercializing our cloud-based distribution model. internationally.
Paragraph 144 · 21% changed Every version of it
The clinical laboratory testing industry is highly regulated, and failure to comply with applicable regulatory, supervisory, accreditation, registration or licensing requirements may adversely affect our business, financial condition and results of operations. In particular, the laws and regulations governing the marketing and research of clinical diagnostic testing are extremely complex and in many instances there are no clear regulatory or judicial interpretations of these laws and regulations, increasing the risk that we may be found to be in violation of these laws.

MD&A

64 paragraphs · 3 new · 27 reworded · 5 gone · 10-K Feb 27, 2026 against Feb 28, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 41 · 48% changed
Cost Amortization of licensing and other revenues for acquired intangibles increased by $1.7 million, or 100%, in the year ended December 31, 2024, when 2025 compared to the year ended December 31, 2023, increased by approximately $0.2 million, or 14.4%, primarily due 2024. The increase was attributed to a net increase in costs to support our collaborative agreements. the amortization of intangibles acquired as part of the business combination with Foresight Diagnostics.
Paragraph 44 · 44% changed
Interest and other income Income tax benefit (expense) increased by $18.9 $60.6 million, or 77.6%, 8,722.9%, in the year ended December 31, 2024, 2025, compared to the same period in the prior year, primarily due to greater average cash and investment balances driving higher interest income. a tax benefit from a partial release of the valuation allowance in connection with the acquisition of Foresight Diagnostics. See Note 3, Business Combination, for further details.
Paragraph 55 · 25% changed
Cash provided by used in investing activities for the year ended December 31, 2024 2025 totaled $137.6 $132.2 million, which was comprised of $24.8 million from proceeds from sale of investments and $314.4 million from proceeds of investment maturities, offset by $122.0 million in purchasing of new investments, $66.4 $106.2 million in acquisitions of property and equipment, $2.7 million for investment $33.0 in related party, and $10.5 million for an purchase of intangible asset acquisition. and $16.0 million in acquisition of business offset by $23.0 million from proceeds of investments maturities.
Paragraph 53 · 24% changed
Cash provided by operating activities during the year ended December 31, 2024 2025 was $135.7 $215.3 million. The net loss of $190.4 $208.2 million includes $324.0 $413.5 million in non-cash charges resulting from $31.0 $41.8 million of depreciation and amortization, $274.4 $1.7 million of amortization of acquired intangibles, $354.4 million of stock-based compensation expense, $15.3 $20.2 million of non-cash lease expense, $1.0 million for amortization of debt discount and issuance cost, $0.5 million for foreign exchange adjustment, and $2.8 million of non-cash interest expense, offset by a $0.6 $3.2 million decrease change in amortization fair value of premiums warrants and accretion of purchase discounts on investment securities preferred stock and a $0.4 $1.4 million decrease in non-cash expense recovery. Operating assets had cash outflows of $29.1 $4.6 million resulting from a $35.9 $20.9 million increase in accounts receivable, inventory and a $4.0 $8.6 million increase in inventory, offset by a $10.8 million decrease in prepaid expenses and other assets, offset by a $20.7 million decrease in accounts receivable and a $4.2 million decrease in operating lease right-of-use assets. Operating liabilities resulted in had cash inflows of $31.2 $14.6 million resulting from a $13.2 $60.3 million increase in accrued compensation, a $0.8 million increase in accounts payable, a $40.3 $31.3 million increase in other accrued compensation, liabilities, and a $0.9 $2.8 million increase in deferred revenue, offset by a $16.8 $60.8 million decrease in deferred tax liability and a $19.8 million decrease in lease liabilities and a $6.4 million decrease in other accrued liabilities.
Paragraph 18 · 24% changed
Revenues recognized from tests processed through our Constellation model, and from our strategic partnership agreements (which during the three years ended December 31, 2024, 2023 and 2022 comprised BGI Genomics Co. Ltd., and Foundation Medicine, Inc. agreements) are reported in licensing and other revenues. We also recognize licensing revenues through the licensing and the provisioning of services to support the use of our proprietary technology by licensees under our cloud-based distribution model. As of December 31, 2024, we are recognizing revenues on 7 licensing and service arrangements with laboratories under our Constellation model.
Paragraph 43 · 21% changed
Interest and other income increased by $18.9 $2.6 million, or 77.6%, 6.1%, in the year ended December 31, 2024, 2025, compared to the same period in the prior year, primarily due to greater average cash and investment balances driving higher interest income. unrealized gains on warrant valuations.
Paragraph 30 · 19% changed
Stock-based compensation expense for restricted stock units and stock options with performance metrics is calculated based upon probability of achievement of the metrics specified in the grant. Stock-based compensation expense for performance-based awards is recognized when it becomes probable that the performance conditions will be met. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards. No compensation cost is recognized on stock options for employees and non-employees who do not render the requisite service and therefore forfeit their rights to the stock options. The measurement of stock-based compensation is subject to periodic adjustments as potential adjustment based on the underlying equity instruments that ultimately vest, and with the resulting change in value, if any, is recognized in our statements of operations and comprehensive loss during the period that the related services are rendered.
Paragraph 39 · 18% changed
Research and development expenses during the year ended December 31, 2024 2025 increased by $83.5 $220.0 million, or 26.0%, 54.4%, when compared to the year ended December 31, 2023. 2024. The increase was driven by a $48.3 attributable to an increase of $127.3 million increase in salary and related expenditures, which includes compensation expenditures (including a $24.2 $32.0 million increase in stock-based compensation expense, expense), a $25.7 million increase in lab and clinical trial related expenses, a $6.7 $19.4 million increase in consulting expenses, a $21.6 million increase in office related expenses, a $40.9 million increase in lab related and clinical trial expenses, a $2.8 $6.5 million net increase in office, facilities, facilities related expenses and a $4.3 million increase in travel and other expenses.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors224 words changed in this paragraph; it is 41% similar to last year's version.
We currently offer a number of genetic tests, and each of those tests is an LDT. The FDA considers an LDT to be a test that is designed, developed, validated and used within a single laboratory. Our laboratories are currently regulated under CLIA and must comply with CAP requirements, and we are subject to extensive federal and state laws and regulations. The FDA has historically taken the position that it has the authority to regulate LDTs as medical devices under the FDC Act, but it had generally exercised enforcement discretion with regard to such tests. The issued a final rule issued by FDA in May 2024, discussed 2024 that would have subjected many LDTs to regulatory requirements including, in some cases, premarket authorization. A federal district court vacated the section of this Annual Report on Form 10-K entitled “Business—Government Regulations—FDA”, could have FDA final rule in May 2025, holding that LDTs are not subject to FDA regulation. FDA rescinded the final rule in September 2025. FDA has not indicated how it will interpret the court ruling or whether it will seek a significant impact on our ability to market current LDTs and to develop new ones in the future. Although our LDTs marketed prior to May 6, 2024 may be eligible for enforcement discretion different regulatory approach with respect to premarket review requirements, changes we make LDTs or components thereof. In June 2025 Congress re-introduced the Verifying Accurate, Leading-edge IVCT Development Act, or VALID Act, to establish a new risk-based regulatory framework for in vitro clinical tests, or IVCTs, including IVDs, LDTs, collection devices and instruments used with such LDTs, as well as new LDTs we develop after that date, will be subject to various regulatory requirements such as those described tests. This legislation was previously introduced in this risk factor. 2021 and 2023.

Source: Item 1A, 10-K 0001104659-26-020881 vs Item 1A, 10-K 0001558370-25-001869

MD&A178 words changed in this paragraph; it is 43% similar to last year's version.
We currently provide a comprehensive suite of products to improve patient care outcomes in three main areas of healthcare – oncology, women’s health, oncology, and organ health, and our Constellation cloud-based platform. health. We generate a the majority of our revenues from the sale of Panorama, our non-invasive prenatal test, or NIPT, as well as test (“NIPT”) and Horizon, our Carrier Screening genetic carrier screening test. In addition to Panorama and Horizon, Panorama, our product offerings in women’s health include Spectrum Preimplantation Genetics, Fetal Focus, our Anora miscarriage test, noninvasive prenatal test for single-gene inherited conditions, Vistara, our single-gene NIPT that screens for conditions that may affect quality of life, and Vistara single-gene NIPT, as well as Anora, our Empower test to help determine underlying reasons for occurrence of miscarriage, and Empower, our hereditary cancer screening test, test which we also offer through our oncology sales channel. In oncology, we offer Signatera, our personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer. We also offer Latitude, our Signatera molecular residual disease blood-based MRD test for oncology applications, which we commercialize colorectal cancer that does not require a tumor tissue sample, as well as Altera, a comprehensive genomic profiling test run in our CLIA (as defined below) laboratories to support treatment decisions and offer on a research use only basis to research laboratories and pharmaceutical companies; and our Prospera organ transplant assessment tests. therapy selection.

Source: Item 7, 10-K 0001104659-26-020881 vs Item 7, 10-K 0001558370-25-001869

Legal Proceedings133 words changed in this paragraph; it is 70% similar to last year's version.
The Company is involved in two lawsuits against Guardant Health, Inc. (“Guardant”). In May 2021, Guardant filed suit against the Company in the United States District Court of the Northern District of California alleging false advertising and related claims and seeking unspecified damages and injunctive relief. Also in May 2021, the Company filed suit against Guardant in the Western District of Texas, alleging false advertising and related claims. The Company has voluntarily dismissed its Texas suit against Guardant and has asserted the claims from the Texas action as counterclaims in the California action, seeking unspecified damages and injunctive relief. In August 2021, Guardant moved to dismiss the Company’s counterclaims, which motion was denied in all material respects. Both parties filed cross-motions for summary judgment, which were granted in part and denied in part. In November 2024, after trial, the jury returned a verdict finding the Company liable for false advertising and found damages of $292.5 million. A On July 28, 2025, the Court entered a final order regarding the parties’ post-trial motions, which largely upheld the jury verdict. The Court has not issued a final judgment at this time. The Company plans to appeal the final judgment to the Ninth Circuit Court of Appeals. In February 2025, Guardant filed suit against the Company and two of its former employees who recently joined the Company in the United States District Court for the Northern District of California, alleging trade secret misappropriation, breach of contract and related tort claims, seeking unspecified damages and injunctive relief. Concurrently with the filing of the complaint, Guardant also moved for a temporary restraining order and expedited discovery, which motions Guardant subsequently withdrew. In April 2025, Guardant voluntarily dismissed its claims against the Company and the employee defendants without prejudice.

Source: Item 3, via Note 10 – Commitments and Contingencies, 10-K 0001104659-26-020881 vs Item 3, via Note 8 – Commitments and Contingencies, 10-K 0001558370-25-001869

Accounting Policies130 words changed in this paragraph; it is 42% similar to last year's version.
The preparation of financial statements in accordance conformity with generally accepted accounting principles (GAAP) in the United States requires management to make estimates judgments, estimates, and assumptions about future events that could affect the reported amounts of assets and liabilities reported, disclosures about contingent assets at the date of the financial statements and liabilities, and the reported amounts of revenues revenue and expenses. Significant items subject to such estimates include stock-based compensation, expenses during the fair value of options, and the expected consideration (average selling price) to be received from contracts with customers, insurance payors, and patients. These estimates and assumptions are based on management's best estimates and judgment. Management regularly evaluates reporting period. The Company bases its estimates and assumptions using on historical experience and on various other factors, including contractual terms assumptions it believes to be applicable and statutory limits; however, actual evaluates them on an ongoing basis to ensure they remain reasonable under current conditions. Actual results could differ significantly from these estimates and could have an adverse effect on the Company's financial statements. those estimates.

Source: Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001104659-26-020881 vs Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001558370-25-001869

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of NTRA's Risk Factors and MD&A, 10-K Feb 27, 2026 against 10-K Feb 28, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
We are incorporating artificial intelligence, or AI, and machine learning, or ML, technologies into aspects of our business. The development and use of these technologies involve operational, regulatory, legal, and reputational risks that could adversely affect our business, results of operations, and financial condition.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
AI and ML systems are complex and may generate inaccurate or unintended outputs due to design limitations, algorithmic flaws, or deficiencies in training data. Reliance on such outputs could result in errors in judgment or operational inefficiencies. These technologies may also introduce information security risks, including vulnerabilities to cyberattacks, unauthorized access, or system disruptions affecting the confidentiality, integrity, or availability of data.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
Our use of AI and ML may increase data privacy and intellectual property risks. Inadequate governance, controls, or training could result in data breaches, loss of confidential and proprietary information, unauthorized disclosure of personal data, including PHI, or other misuse of our proprietary information, leading to regulatory investigations, litigation, or reputational harm.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
The regulatory landscape for AI is evolving rapidly. Compliance with emerging laws and guidance, including the European Union’s Artificial Intelligence Act, evolving FDA guidance, and state privacy laws, may increase costs, require operational changes, or limit certain AI applications. Regulatory developments or shifts in enforcement priorities could restrict our ability to deploy or modify AI systems. Any failure to comply with applicable requirements could result in enforcement actions, fines, operational restrictions, or other adverse effects on our business and results of operations.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
We have submitted PMAs for Signatera for approval as a companion diagnostic. We may face difficulties in obtaining approval of these PMAs for a variety of reasons, including failure to demonstrate the safety and/or effectiveness of our tests to FDA’s satisfaction. If approval of any of our pending Signatera PMAs is delayed or denied our business could be adversely affected.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
Moreover, our clinical trials to support PMA approval must be conducted under an FDA-approved IDE. FDA has the authority to deny IDE submissions, or to suspend or revoke IDEs once granted, under certain conditions, including noncompliance with FDA requirements or undue risks to subjects. If we are unable to maintain our current IDEs or to obtain IDEs that we may seek in the future, our continued ability to conduct clinical trials could be adversely affected, which could delay or prevent FDA approval. Furthermore, we cannot assure you that these studies, or studies of other tests that we may conduct in the future, will be successful or that they will be sufficient to support FDA approval If approval of any future PMAs for Signatera or any tests we develop in the future is delayed or if we are unable to obtain approval of any such PMAs, our business could be adversely affected.
Read it in 10-K Feb 27, 2026 at sec.gov
Show the other 41
RemovedRisk Factors
utilize our tests, any enforcement action against the supplier by the FDA or any other regulatory authority in the jurisdictions in which our licensees and laboratory distribution partners are located could have an adverse impact on our business.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
payments, which could adversely affect gross margins in future periods. If any of the foregoing were to occur, our business, financial condition, results of operations, cash flows, prospects, or stock price could be adversely affected.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
The reimbursement environment, particularly for molecular diagnostics, is continually changing and our efforts to broaden reimbursement for our tests with third-party payers may not be successful. Third parties, such as commercial health insurers and government programs, from whom we have received reimbursement may withdraw coverage or decrease the amount of reimbursement for our tests at any time and for any reason, or may otherwise adopt requirements, programs or policies that may restrict or adversely affect our business. In addition, in some cases, our tests or their uses
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
Even if we are being reimbursed for our tests, third-party payers may review and adjust the rate of reimbursement, require patient cost-sharing, or stop paying for our tests. Government and commercial third-party payers continue to
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
policies or applicable laws and regulations, we may incur additional training and compliance costs; may, and from time to time do, receive inquiries, such as informal requests for documents, civil investigative demands, and subpoenas, from third-party payers or other third parties, including government entities; or may be held liable or otherwise responsible for such acts of non-compliance. Any of the foregoing could adversely affect our cash flow and financial condition.
Read it in 10-K Feb 28, 2025 at sec.gov
RewordedRisk Factors
If FDA premarket clearance, approval develops an alternate approach to regulating LDTs, or de novo classification is required for any of if Congress enacts legislation giving FDA authority to regulate our existing current or future tests, LDTs, or for any components or materials we use in, or software that we or our customers use as part of, our tests, we may be forced to stop selling our tests or we may be required to modify claims for or make other changes to our tests while we or our suppliers work to obtain comply with FDA clearance, approval or de novo classification. requirements including, potentially, premarket authorization.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
Furthermore, to the extent that we are unable to retain our employees and they leave our company to join one of our competitors, we cannot assure you that any invention, non-disclosure or non-compete agreements we have in place will provide meaningful protection against a departing employee’s unauthorized use or disclosure of our confidential information, as further discussed in “—Risks Relating to our Intellectual Property—If we are not able to adequately protect our trade secrets and other proprietary information, the value of our technology and products could be significantly diminished.”
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
Furthermore, because our licensees under our cloud-based distribution model also exclusively use such sole-sourced components to run the tests they develop based on our technology, and our laboratory distribution partners must use certain of such sole-sourced components in order to utilize our tests, any enforcement action against the supplier by the FDA or any other regulatory authority in the jurisdictions in which our licensees and laboratory distribution partners are located could have an adverse impact on our business.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
While receiving such designations enables us to have increased interactions with FDA, this designation does not change the requirement that we cannot assure you that these designations will lead to accelerated review or approval demonstrate the safety and effectiveness of our regulatory submissions tests for Signatera. each
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
Our overall test volumes grew from approximately 2,066,500 2,496,100 to 2,496,100 3,064,600 and further to 3,064,600 3,525,500 tests processed during the years ended 2022, December 31, 2023, 2024, and 2024, 2025, respectively, and since 2009 in recent years we have launched over 15 launched, and intend to continue to launch, product offerings, enhancements, or and indications.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
Furthermore, any changes to our testing process may require us to use new or different suppliers or materials with whom or which we are unfamiliar, and which may not perform as we anticipate, and could cause delays, downtime or other operational issues.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
An important part of our business strategy is to expand and offer our tests internationally, either by providing our testing services directly or through our laboratory partners, or through our licensees under our Constellation cloud-based distribution model. internationally.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
We currently operate laboratory facilities in Austin, Texas and in Texas, San Carlos, California, both of which process Panorama, Horizon, and Signatera tests, which together represent the significant majority of our revenues. Boulder, Colorado.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
Moreover, we have limited experience forecasting our future financial performance from our new products in these industries that are newer to us, and our actual results may fall below our financial guidance or other projections, or the expectations of analysts or investors, which could cause the price of our common stock to decline.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
From time to time, we have and may in the future enter into transactions to acquire or dispose of businesses, products or technologies or to engage in other strategic transactions, such as our recent acquisition of certain reproductive health assets related to Invitae Corp.’s NIPT and carrier screening business. Foresight Diagnostics.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
Similarly, certain results of the CIRCULATE-Japan study have recently been published, and we cannot assure you that such results will impact professional society or practice guidelines, or coverage and reimbursement determinations from third-party payers, as we anticipate.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
As of December 31, 2024, 2025, we have $80.4 $80.3 million of outstanding balance of the Credit Line balance, including accrued interest. interest, under our credit line with UBS.
Read it in 10-K Feb 27, 2026 at sec.gov
Quiet changesRisk Factors
We host the significant majority of these algorithms on a cloud-based cloud‑based software platform pursuant to an agreement with DNAnexus, Inc., or DNAnexus, and both we and our Constellation licensees access our algorithms through the DNAnexus platform.
Read it in 10-K Feb 27, 2026 at sec.gov
Quiet changesRisk Factors
Either Any of our these laboratories may be harmed or rendered inoperable, or samples could be damaged or destroyed, by natural or manmade disasters, including earthquakes, severe weather, flooding, power outages and contamination, including as a result of a health pandemic, which may render it difficult or impossible for us to perform our tests for some period of time.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
We provide a comprehensive suite of products to improve patient care outcomes in three main areas of healthcare – oncology, women’s health, and organ health. We generate the majority of our revenues from the sale of Panorama, our non-invasive prenatal test (“NIPT”) and Horizon, our genetic carrier screening test. In addition to Panorama, our product offerings in women’s health include Fetal Focus, our noninvasive prenatal test for single-gene inherited conditions, Vistara, our single-gene NIPT that screens for conditions that may affect quality of life, and Anora, our test to help determine underlying reasons for occurrence of miscarriage, and Empower, our hereditary cancer screening test which we also offer through our oncology sales channel. In oncology, we offer Signatera, our personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer. We also offer Latitude, our blood-based MRD test for colorectal cancer that does not require a tumor tissue sample, as well as Altera, a comprehensive genomic profiling test to support treatment decisions and therapy selection.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
The total consideration the Company expects to collect in exchange for the Company’s products is an estimate and may be fixed or variable. Consideration includes reimbursement from both patients and insurance carriers, adjusted for variable considerations related to disallowed cases, percent of patient responsibility collected, refunds and reserves, and is estimated using the expected value method. For insurance carriers and product types with similar reimbursement characteristics, the Company uses a portfolio of relevant historical data to estimate variable consideration and total collections for the Company’s products. The Company constrains the estimated variable consideration when it determines it is probable that a significant reversal in the amount of cumulative revenue recognized may occur in future periods.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
In conjunction with the completion of the Company’s acquisition of Foresight Diagnostics in December 2025, we acquired a developed technology intangible asset for which we determined the acquisition date fair value using a multi-period excess earnings income approach valuation model that discounts expected future cash flows to present value. The expected future cash flows used in the valuation model include significant assumptions that form the basis of the forecasted results, principally the clinical revenue and related growth rate. These significant assumptions are forward-looking and could be affected by future economic and market conditions.
Read it in 10-K Feb 27, 2026 at sec.gov
RemovedMD&A
We currently provide a comprehensive suite of products in women’s health, oncology, and organ health, and our Constellation cloud-based platform. We generate a majority of our revenues from the sale of Panorama, our non-invasive prenatal test, or NIPT, as well as Horizon, our Carrier Screening test. In addition to Panorama and Horizon, our product offerings in women’s health include Spectrum Preimplantation Genetics, our Anora miscarriage test, and Vistara single-gene NIPT, as well as our Empower hereditary cancer screening test, which we also offer through our oncology sales channel. We also offer our Signatera molecular residual disease test for oncology applications, which we commercialize as a test run in our CLIA (as defined below) laboratories and offer on a research use only basis to research laboratories and pharmaceutical companies; and our Prospera organ transplant assessment tests.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
We recognize revenues when, or as, performance obligations in the contracts are satisfied, in the amount reflecting the expected consideration to be received from the goods or services transferred to the customers.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
Product revenues are derived by performing genetic testing services and our performance obligation is complete when test results are delivered to a clinic or patient, who are considered the customer for such services. We enter into contracts with insurance carriers with primarily payment terms related to tests provided to the patients who have health insurance coverage. Insurance carriers are considered to be third-party payers on behalf of the patients, and the patients are considered as the customers who receive genetic test services. Tests may be billed to insurance carriers, patients, or a combination of insurance carriers and patients. Further, we sell tests to a number of domestic and international laboratory partners and identify the laboratory partners as customers provided that there is a test services agreement between us and them.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ December 31, ​ 2024 2023 2022 ​ (in thousands) Cash provided by (used in) operating activities $ 135,664 $ (246,955) $ (431,501) Cash provided by investing activities 137,624 168,498 ​ 330,338 Cash provided by financing activities 30,204 254,461 ​ 482,640 Net change in cash, cash equivalents and restricted cash 303,492 ​ 176,004 ​ 381,477 Cash, cash equivalents and restricted cash, beginning of period 642,095 466,091 ​ 84,614 Cash, cash equivalents and restricted cash, end of year $ 945,587 $ 642,095 $ 466,091
Read it in 10-K Feb 28, 2025 at sec.gov
RewordedMD&A
The increase was driven by a $48.3 attributable to an increase of $127.3 million increase in salary and related expenditures, which includes compensation expenditures (including a $24.2 $32.0 million increase in stock-based compensation expense, expense), a $25.7 million increase in lab and clinical trial related expenses, a $6.7 $19.4 million increase in consulting expenses, a $21.6 million increase in office related expenses, a $40.9 million increase in lab related and clinical trial expenses, a $2.8 $6.5 million net increase in office, facilities, facilities related expenses and a $4.3 million increase in travel and other expenses.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
The net loss of $190.4 $208.2 million includes $324.0 $413.5 million in non-cash charges resulting from $31.0 $41.8 million of depreciation and amortization, $274.4 $1.7 million of amortization of acquired intangibles, $354.4 million of stock-based compensation expense, $15.3 $20.2 million of non-cash lease expense, $1.0 million for amortization of debt discount and issuance cost, $0.5 million for foreign exchange adjustment, and $2.8 million of non-cash interest expense, offset by a $0.6 $3.2 million decrease change in amortization fair value of premiums warrants and accretion of purchase discounts on investment securities preferred stock and a $0.4 $1.4 million decrease in non-cash expense recovery.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
The increase was attributable to a $124.4 an increase of $212.6 million increase in salary and related expenditures, which includes compensation expenditures (including a $55.5 $41.1 million increase in stock-based compensation expense, expense), a $57.2 $25.2 million increase in consulting and legal expenses, a $8.9 $28.5 million increase in marketing costs, expenses, a $7.4 $8.7 million increase in travel expenses, related costs, a $7.4 $14.5 million increase in office related expenses, costs, a $16.5 $9.4 million increase in vendor expenses, a $30.6 million increase in legal related expenses, and a $1.2 $6.4 million net increase in facilities and other costs.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Interest and other income Income tax benefit (expense) increased by $18.9 $60.6 million, or 77.6%, 8,722.9%, in the year ended December 31, 2024, 2025, compared to the same period in the prior year, primarily due to greater average cash and investment balances driving higher interest income. a tax benefit from a partial release of the valuation allowance in connection with the acquisition of Foresight Diagnostics.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Operating liabilities resulted in had cash inflows of $31.2 $14.6 million resulting from a $13.2 $60.3 million increase in accrued compensation, a $0.8 million increase in accounts payable, a $40.3 $31.3 million increase in other accrued compensation, liabilities, and a $0.9 $2.8 million increase in deferred revenue, offset by a $16.8 $60.8 million decrease in deferred tax liability and a $19.8 million decrease in lease liabilities and a $6.4 million decrease in other accrued liabilities.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Product revenues generated from our testing accounted for $2,295.8 million or nearly 100% of total revenues for the year ended December 31, 2025, compared to $1,685.1 million or 99% of total revenues for the year ended December 31, 2024, compared to 2024 and $1,068.5 million or 99% of total revenues for the year ended December 31, 2023 and $797.3 million or 97% of total revenues for the year ended December 31, 2022. 2023.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Operating assets had cash outflows of $29.1 $4.6 million resulting from a $35.9 $20.9 million increase in accounts receivable, inventory and a $4.0 $8.6 million increase in inventory, offset by a $10.8 million decrease in prepaid expenses and other assets, offset by a $20.7 million decrease in accounts receivable and a $4.2 million decrease in operating lease right-of-use assets.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
The number of tests that we process is a key metric as it tracks overall volume growth, particularly as our laboratory partners may transition from sending samples to our laboratory to our cloud- cloud-based distribution model, as a result of which our tests accessioned would decrease but our tests processed would remain unchanged.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Revenues recognized from tests processed through our Constellation model, and from our strategic partnership agreements (which during the three years ended December 31, 2024, 2023 are reported in licensing and 2022 comprised BGI Genomics Co. other revenues.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Interest and other income increased by $18.9 $2.6 million, or 77.6%, 6.1%, in the year ended December 31, 2024, 2025, compared to the same period in the prior year, primarily due to greater average cash and investment balances driving higher interest income. unrealized gains on warrant valuations.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Interest expense decreased by $2.0 $6.6 million, 15.5%, 61.9%, in the year ended December 31, 2024 2025 compared to the same period in the prior year primarily as a result of the slight decrease in interest rate and due to the redemption of the Convertible Notes in October 2024.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Revenues For the year ended December 31, 2024, revenues from customers outside the United States were $39.2 million, representing approximately 2% of total revenues for the year ended December 31, 2024. revenues.
Read it in 10-K Feb 27, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/NTRA/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.